Clinical trials: Movement Abnormalities
Parkinson's Disease
Extended Long-Term Safety Study of KW-6500
This is a extended long-term safety study in Parkinson's disease patients who have motor response complications on levodopa therapy and completed 12 weeks administrations of KW-6500 in 6500-004 study.
- Trial name
- 6500-005 (NCT01063621)
- Testing
- KW-6500
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Multiple System Atrophy
Safinamide for Multiple System Atrophy (MSA)
The study is a placebo controlled study, with two parallel arms, in which participants will be randomly assigned in a 2:1 ratio to receive either active (200 mg safinamide) or placebo in a double blind manner.
- Trial name
- NCT03753763
- Testing
- Safinamide Methanesulfonate
- Where
- 19 sites in Italy, Spain
- Volunteers
- 49 people
- Sponsor
- Zambon SpA
Spinal Cord Stimulation, Deep Brain Stimulation
Implantable Systems Performance Registry
The Implantable Systems Performance Registry (ISPR) was developed to evaluate the long-term reliability and performance of market-released Medtronic Neuromodulation infusion and stimulation products.
- Conditions
- Spinal Cord Stimulation, Deep Brain Stimulation, Drug Infusion (Implantable Pumps), Sacral Neuromodulation
- Trial name
- ISPR (NCT00959296)
- Testing
- Various
- Where
- 50 sites in United States, Austria and 5 more
- Volunteers
- 10,981 people
- Sponsor
- MedtronicNeuro
Parkinson's Disease
SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)
The objective of the Post Marketing Surveillance Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson.
- Trial name
- NCT00727727
- Testing
- Piribedil
- Where
- 2 sites in Germany
- Volunteers
- 750 people
- Sponsor
- Desitin Arzneimittel GmbH
Parkinson's Disease
Non-interventional, Retrospective, Multi-center Study to Evaluate Non-motor Symptoms in Advanced Parkinson Disease (PD) Patients Already Treated With Rotigotine
This is an observational, non-interventional and retrospective study in patients with advanced PD who have been treated with Rotigotine (Neupro®) as prescribed by physicians according to usual clinical practice in Spain.
- Trial name
- RETO-PD (NCT01504529)
- Where
- 59 sites in Spain
- Volunteers
- 391 people
- Sponsor
- UCB Pharma
Parkinson Disease
Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants
The primary purpose of this study is to evaluate the effect of carbamazepine, a strong CYP3A4 inducer, on the steady-state pharmacokinetics (PK) of tavapadon in healthy adult participants.
- Trial name
- NCT05581823
- Testing
- Tavapadon, Carbamazepine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Cerevel Therapeutics, LLC
Parkinson Disease
A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects
The purpose of this study was to investigate the safety, tolerability, pharmacokinetics and catechol-O-methyltransferase (COMT) activity of BIA 9-1067 in healthy male subjects after single oral ascending doses.
- Trial name
- NCT01520727
- Testing
- BIA 9-1067
- Where
- France
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Symptomatic Neurogenic Orthostatic Hypotension
Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
To evaluate the time to treatment intervention in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH)…
- Trial name
- RESTORE (NCT02586623)
- Testing
- Droxidopa capsules
- Where
- 168 sites in United States
- Volunteers
- 453 people
- Sponsor
- H. Lundbeck A/S
Parkinson's Disease, Off Episodes of Parkinson Disease
A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
A cardiac safety study of an investigational drug to see how it affects the heart in people with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
- Trial name
- NCT03187301
- Testing
- APL-130277, Moxifloxacin
- Where
- 15 sites in United States, Italy
- Volunteers
- 48 people
- Sponsor
- Sumitomo Pharma America, Inc.
Huntington Disease
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies
This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in participants who have completed other F.
- Trial name
- NCT03842969
- Testing
- RO7234292 (RG6042)
- Where
- 38 sites in United States, Austria and 6 more
- Volunteers
- 236 people
- Sponsor
- Hoffmann-La Roche
Tourette Syndrome
A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
Standard placebo-controlled, double-blind study design (TEV-50717 [low dose and high dose] vs. placebo in a 1:1:1 ratio) was chosen to determine whether study drug treatment results in a statistically significant effect on the…
- Trial name
- ARTISTS2 (NCT03571256)
- Testing
- TEV-50717
- Where
- 56 sites in United States, Argentina and 8 more
- Volunteers
- 158 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson''s Disease
Pilot Study of Safety and Efficacy of Spheramine
Tolerability and Efficacy of Spheramine will be evaluated after operative implantation (Stereotactic Intrastriatal Implantation) in patients with advanced Parkinson's Disease
- Trial name
- NCT00761436
- Testing
- Spheramine (BAY86-5280)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Bayer
Parkinson Disease, Parkinson's Disease
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease
- Trial name
- NCT00632736
- Testing
- Ropinirole XL (formerly CR)
- Where
- 75 sites in United States, Belgium and 7 more
- Volunteers
- 419 people
- Sponsor
- GlaxoSmithKline
Essential Tremor
A Pilot Study of the Cala ONE Device for Essential Tremor
Prospective, multi-center, randomized, controlled study designed to evaluate safety and repeatable effectiveness. Subjects will be randomized 2:1:1 to transcutaneous afferent patterned stimulation (TAPS), sham, or 'no…
- Trial name
- EXCITE (NCT03152136)
- Testing
- Cala ONE device
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- Cala Health, Inc.
Parkinson Disease
Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)
This is a randomized, double-blind, single center, phase 2 study to assess efficacy and safety of multiple allogeneic HB-adMSCs vs Placebo for the treatment of Parkinson's disease.
- Trial name
- NCT04995081
- Testing
- Biological/Vaccine: Allogeneic HB-adMSCs
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Hope Biosciences Research Foundation
Parkinsonian Syndromes
A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms
Patients come to their doctor showing possible symptoms of a movement disorder. It is possible that these symptoms may get worse over time. There is more than one disease that can cause such symptoms.
- Trial name
- NCT00382967
- Testing
- DaTSCAN SPECT imaging
- Where
- 2 sites in United States, France
- Volunteers
- 273 people
- Sponsor
- GE Healthcare
Tourette Syndrome
Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
Phase 2, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 administered once daily (qd) for a total of 8 weeks of treatment.
- Trial name
- NCT02581865
- Testing
- NBI-98854
- Where
- 30 sites in United States
- Volunteers
- 124 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease
Spectroscopy in Parkinson Disease
The primary objective of the study is to determine the utility of blood plasma infrared spectroscopy (biospectroscopy) in distinguishing subjects with idiopathic Parkinson's disease from healthy controls.
- Trial name
- SPIN-PD (NCT01005030)
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Molecular Biometrics, Inc.
Heart Failure, Myocardial Infarction
PARACHUTE III Pressure Volume Loop Sub-Study
The primary objective is to assess the longterm safety of the CardioKinetix Parachute Implant and Delivery System in the partitioning of the left ventricle in patients with heart failure due to ischemic heart disease.
- Trial name
- PIII PV Loop (NCT02241837)
- Where
- 3 sites in Belgium, Italy and 1 more
- Volunteers
- 11 people
- Sponsor
- CardioKinetix, Inc
Parkinson's Disease
A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa
This study evaluated the pharmacokinetics, motor effects, and assessed the safety of IPX066 compared with an immediate-release cabridopa-levodopa formulation in subjects with advanced Parkinson's disease.
- Trial name
- NCT00869791
- Testing
- IPX066, IR CD-LD
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Impax Laboratories, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.